Dominique Heymann
#158,027
Most Influential Person Now
Researcher
Dominique Heymann's AcademicInfluence.com Rankings
Dominique Heymannbiology Degrees
Biology
#12294
World Rank
#15760
Historical Rank
Biotechnology
#216
World Rank
#218
Historical Rank
Genetics
#1351
World Rank
#1453
Historical Rank
Molecular Biology
#1978
World Rank
#2010
Historical Rank
Download Badge
Biology
Dominique Heymann's Degrees
- PhD Biomedical Sciences Université Paris Cité
- Masters Biotechnology Université Paris Cité
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Dominique Heymann Influential?
(Suggest an Edit or Addition)Dominique Heymann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. (2004) (614)
- IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. (2004) (596)
- Osteoclastic resorption of calcium phosphate ceramics with different hydroxyapatite/beta-tricalcium phosphate ratios. (1997) (402)
- Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling (2012) (374)
- Mechanisms of bone repair and regeneration. (2009) (290)
- Autophagy in osteoblasts is involved in mineralization and bone homeostasis (2014) (272)
- Human breast cancer cells educate macrophages toward the M2 activation status (2015) (267)
- Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. (2003) (246)
- RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. (2004) (232)
- Recent advances in TGF-β effects on chondrocyte metabolism (2002) (217)
- Current Therapeutic Strategies and Novel Approaches in Osteosarcoma (2013) (203)
- Osteoclastic acidification pathways during bone resorption. (2002) (190)
- gp130 Cytokine family and bone cells. (2000) (185)
- Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. (2016) (172)
- Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. (2007) (164)
- Osteogenic potential in vitro of human bone marrow cells cultured on macroporous biphasic calcium phosphate ceramic. (1999) (160)
- RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases (2007) (154)
- Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment (2015) (153)
- Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice (2005) (150)
- Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. (2002) (144)
- Influence of biphasic calcium phosphate granulometry on bone ingrowth, ceramic resorption, and inflammatory reactions: preliminary in vitro and in vivo study. (1999) (140)
- The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. (2017) (136)
- Cancer stem cells in osteosarcoma. (2017) (134)
- Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. (2008) (132)
- Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients (2011) (131)
- Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. (2005) (130)
- Bisphosphonates: new therapeutic agents for the treatment of bone tumors. (2004) (125)
- Bone tissue formation with human mesenchymal stem cells and biphasic calcium phosphate ceramics: the local implication of osteoclasts and macrophages. (2014) (124)
- Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle (2014) (122)
- Carotid and femoral atherosclerotic plaques show different morphology. (2011) (122)
- Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers (2015) (122)
- RANK–RANKL signalling in cancer (2016) (119)
- Osteoprotegerin: multiple partners for multiple functions. (2013) (117)
- Interleukin‐34 is expressed by giant cell tumours of bone and plays a key role in RANKL‐induced osteoclastogenesis (2010) (112)
- Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence (2010) (112)
- Mifamurtide for the treatment of nonmetastatic osteosarcoma (2011) (107)
- Osteoclastic resorption of biphasic calcium phosphate ceramic in vitro. (1997) (106)
- Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate (2013) (105)
- Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer (2019) (105)
- Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis (2016) (104)
- Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. (2015) (104)
- Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma (2016) (101)
- DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. (2007) (101)
- Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma Status (2007) (100)
- Concise Review: Embryonic Stem Cells: A New Tool to Study Osteoblast and Osteoclast Differentiation (2007) (97)
- Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B (2007) (93)
- Sarcoma treatment in the era of molecular medicine (2020) (90)
- Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. (2010) (89)
- Biology of Bone Sarcomas and New Therapeutic Developments (2017) (87)
- Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. (2010) (86)
- Proteoglycans: key partners in bone cell biology (2007) (84)
- Key roles of the OPG–RANK–RANKL system in bone oncology (2007) (80)
- Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma (2014) (79)
- Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK (2006) (78)
- Cellular mechanisms of calcium phosphate ceramic degradation. (1999) (78)
- Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. (2010) (77)
- Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. (2007) (76)
- Cytokines, growth factors and osteoclasts. (1998) (75)
- Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 (2004) (73)
- High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular characterization and cellular distribution. (1992) (72)
- Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation (2009) (72)
- Induction of bone formation by activated monocytes / macrophages depends on Oncostatin M signaling (2012) (71)
- Zebrafish xenograft models of cancer and metastasis for drug discovery (2017) (70)
- Synchrotron hard x-ray microprobe: Fluorescence imaging of single cells (2001) (67)
- Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma (2005) (65)
- Osteosarcoma: current status of immunotherapy and future trends (Review). (2006) (65)
- Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity (2019) (64)
- Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. (1998) (64)
- Syndecan-1 regulates the biological activities of interleukin-34. (2015) (63)
- Osteoprotegerin differentially regulates protease expression in osteoclast cultures. (2002) (63)
- Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival* (2009) (62)
- Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. (2004) (62)
- The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets (2011) (61)
- OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. (2006) (61)
- Human Growth Hormone Locally Released in Bone Sites by Calcium‐Phosphate Biomaterial Stimulates Ceramic Bone Substitution Without Systemic Effects: A Rabbit Study (1998) (60)
- Hamstring insertion site healing after anterior cruciate ligament reconstruction in patients with symptomatic hardware or repeat rupture: a histologic study in 12 patients. (2003) (59)
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. (2014) (58)
- Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. (2014) (58)
- RANKL/RANK/OPG: key therapeutic target in bone oncology. (2008) (58)
- Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival (2010) (58)
- A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis (2009) (58)
- IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. (2011) (57)
- Drugs in early clinical development for the treatment of osteosarcoma (2016) (56)
- Regulation of osteoclast protease expression by RANKL. (2003) (56)
- RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. (2006) (53)
- Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. (2004) (52)
- Pericyte-Like Progenitors Show High Immaturity and Engraftment Potential as Compared with Mesenchymal Stem Cells (2012) (52)
- Targeted therapies for bone sarcomas. (2013) (52)
- Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries (2018) (51)
- Orthopaedic implant failure: aseptic implant loosening--the contribution and future challenges of mouse models in translational research. (2014) (49)
- Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. (2012) (49)
- Osteoimmunology of Oral and Maxillofacial Diseases: Translational Applications Based on Biological Mechanisms (2019) (49)
- Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony‐forming cells properties (2011) (49)
- Autophagy: A protective mechanism in response to stress and inflammation. (2006) (48)
- BYL719, a new α‐specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma (2015) (47)
- Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival (2006) (47)
- Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53 (2007) (47)
- Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. (2009) (46)
- Proteases and bone remodelling. (2009) (46)
- IL-1β and TNFα Promote Monocyte Viability through the Induction of GM-CSF Expression by Rheumatoid Arthritis Synovial Fibroblasts (2014) (46)
- Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma (2008) (45)
- Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme (2020) (45)
- Biological activities of sustained polymyxin B release from calcium phosphate biomaterial prepared by dynamic compaction: an in vitro study. (1999) (45)
- Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. (2017) (44)
- Osteoprotegerin, Pericytes and Bone-Like Vascular Calcification Are Associated with Carotid Plaque Stability (2014) (43)
- Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. (2006) (43)
- Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. (2008) (42)
- Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13. (2010) (42)
- Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models (2014) (42)
- Bone Like Arterial Calcification in Femoral Atherosclerotic Lesions: Prevalence and Role of Osteoprotegerin and Pericytes. (2016) (41)
- Ultrastructural evidence in vitro of osteoclast-induced degradation of calcium phosphate ceramic by simultaneous resorption and phagocytosis mechanisms. (2001) (41)
- Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine (2018) (40)
- Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells. (2015) (40)
- Interaction of Cutibacterium ( formerly Propionibacterium) acnes with bone cells: a step toward understanding bone and joint infection development (2017) (40)
- Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body (2007) (40)
- Biodegradation of synthetic biphasic calcium phosphate by human monocytes in vitro: a morphological study. (1996) (38)
- Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1 (2016) (38)
- Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? (2019) (37)
- Distinct Roles of Bcl-2 and Bcl-Xl in the Apoptosis of Human Bone Marrow Mesenchymal Stem Cells during Differentiation (2011) (37)
- The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. (2019) (37)
- ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis. (2016) (37)
- Cytokine production by human thymic epithelial cells: control by the immune recognition of the neurohypophysial self-antigen (1996) (37)
- Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient (2011) (36)
- Therapeutic approach of primary bone tumours by bisphosphonates. (2010) (36)
- Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases (2015) (36)
- New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance (2013) (35)
- Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. (2009) (35)
- mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. (2007) (35)
- IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. (2015) (34)
- Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model. (2015) (34)
- Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do? (2018) (33)
- miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors (2016) (33)
- The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis (2021) (33)
- Sex-specific autophagy modulation in osteoblastic lineage: a critical function to counteract bone loss in female (2016) (33)
- Oncostatin M is a growth factor for Ewing sarcoma. (2012) (33)
- Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models (2011) (32)
- Growth hormone-loaded macroporous calcium phosphate ceramic: in vitro biopharmaceutical characterization and preliminary in vivo study. (1998) (32)
- Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo (2008) (32)
- The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases (2018) (32)
- Osteoclasts in RA: diverse origins and functions. (2013) (31)
- Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells (2008) (31)
- Mechanistic study of the proangiogenic effect of osteoprotegerin (2013) (31)
- TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. (2012) (31)
- OPG, RANK and RANK ligand expression in thyroid lesions (2008) (30)
- LPS increases biomaterial degradation by human monocytes in vitro. (1997) (30)
- Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases (2008) (30)
- TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models (2016) (30)
- Bone Morphogenetic Protein 2 and Transforming Growth Factor β1 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts. (2017) (30)
- Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma (2015) (29)
- Connexin43 intercellular communication drives the early differentiation of human bone marrow stromal cells into osteoblasts (2018) (29)
- Bone sarcomas in the immunotherapy era (2020) (29)
- Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences (2012) (29)
- Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in rankl-induced osteoclastogenesis (2010) (29)
- Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models (2010) (28)
- Modulation by soluble factors of gelatinase activities released by osteoblastic cells. (2000) (28)
- Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid. (2015) (27)
- Molecular Alterations Associated with Osteosarcoma Development (2012) (27)
- Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. (2009) (27)
- Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? (2009) (27)
- Oxytocin Reverses Osteoporosis in a Sex-Dependent Manner (2015) (27)
- Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status (2015) (27)
- Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression (2015) (27)
- Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma (2013) (27)
- Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. (2002) (27)
- Transmission FT-IR microspectroscopy of mineral phases in calcified tissues. (1998) (26)
- Metatarsal Giant Cell Tumors and Giant Cell Reparative Granuloma are Similar Entities (2003) (26)
- Influence of metal ion solutions on rabbit osteoclast activities in vitro. (2002) (26)
- Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. (2014) (26)
- A One‐Pot Synthesis of 1‐Hydroxy‐1,1‐bis(phosphonic acid)s Starting from the Corresponding Carboxylic Acids (2011) (25)
- Anti-Metastatic Properties of a Marine Bacterial Exopolysaccharide-Based Derivative Designed to Mimic Glycosaminoglycans (2016) (25)
- Effects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology. (2011) (25)
- The Challenges of Detecting Circulating Tumor Cells in Sarcoma (2016) (25)
- L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. (2016) (24)
- Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. (2002) (24)
- Drug resistance in glioblastoma: are persisters the key to therapy? (2020) (24)
- Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement (2014) (24)
- Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration (2014) (24)
- Presence of leukaemia inhibitory factor (LIF) and LIF-receptor chain (gp190) in osteoclast-like cells cultured from human giant cell tumour of bone. Ultrastructural distribution. (1999) (24)
- Direct anti‐cancer effect of oncostatin M on chondrosarcoma (2011) (24)
- Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice (2019) (24)
- Bone sarcomas: pathogenesis and new therapeutic approaches (2011) (23)
- Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue (2013) (23)
- Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. (2017) (23)
- Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling. (2017) (22)
- Metastatic osteosarcoma challenged by regorafenib. (2019) (22)
- Neointimal Hyperplasia after Stenting in a Human Mammary Artery Organ Culture (2004) (22)
- Low‐Dose Pesticide Mixture Induces Senescence in Normal Mesenchymal Stem Cells (MSC) and Promotes Tumorigenic Phenotype in Premalignant MSC (2017) (22)
- Ultrastructural study of degradation of calcium phosphate ceramic by human monocytes and modulation of this activity by HILDA/LIF cytokine. (1996) (22)
- Are Fluorescent Organic Nanoparticles Relevant Tools for Tracking Cancer Cells or Macrophages? (2015) (22)
- Implication of molecular vascular smooth muscle cell heterogeneity among arterial beds in arterial calcification (2018) (21)
- Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. (2005) (21)
- First Preclinical Imaging of Primary Cartilage Neoplasm and Its Local Recurrence Using 99mTc-NTP 15-5 Radiotracer (2009) (21)
- Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies (2012) (21)
- Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. (2011) (21)
- Proteoglycans on bone tumor development. (2010) (20)
- Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity. (2020) (20)
- Leukaemia inhibitory factor (LIF) production in pleural effusions: comparison with production of IL-4, IL-8, IL-10 and macrophage-colony stimulating factor (M-CSF). (1996) (20)
- Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations (2018) (20)
- A New Experimental Rat Model of Osteosarcoma Established by Intrafemoral Tumor Cell Inoculation, Useful for Biology and Therapy Investigations (2005) (20)
- Human breast cancer cells educate macrophages toward the M 2 activation status (20)
- Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy (2018) (20)
- Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth (2012) (19)
- Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper (2020) (19)
- Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta (2013) (19)
- Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis. (2013) (19)
- Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma. (2018) (19)
- Association of human growth hormone and calcium phosphate by dynamic compaction: in vitro biocompatibility and bioactivity. (1997) (18)
- Osteoblastic and osteoclastic differentiation of human mesenchymal stem cells and monocytes in a miniaturized three-dimensional culture with mineral granules. (2014) (18)
- A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. (2013) (18)
- Bone Cancer Progression and Therapeutic Approaches (2009) (18)
- Dlx homeobox gene family expression in osteoclasts (2010) (18)
- Synchrotron-induced X-ray microfluorescence on single cells (2001) (18)
- Bone cancer : primary bone cancer and bone metastases (2015) (17)
- Oncostatin M stimulates macrophage-polykaryon formation in long-term human bone-marrow cultures. (1998) (17)
- Development of a per-operative procedure for concentrated bone marrow adjunction in postero-lateral lumbar fusion (2012) (17)
- TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model (2020) (17)
- Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw. (2016) (17)
- The vertebral interbody grafting site’s low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrow (2005) (17)
- Conditioned media from mouse osteosarcoma cells promote MC3T3‐E1 cell proliferation using JAKs and PI3‐K/Akt signal crosstalk (2008) (17)
- Upmodulation of αvβ1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: Correlation with increased cell adhesion on fibronectin (1995) (17)
- TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. (2015) (16)
- Computational model combined with in vitro experiments to analyse mechanotransduction during mesenchymal stem cell adhesion. (2013) (16)
- Sphingolipid distribution at mitochondria-associated membranes (MAMs) upon induction of apoptosis[S] (2020) (16)
- Osteoprotegerin: a new therapeutic agent for the treatment of bone disease. (2001) (16)
- Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma (2018) (16)
- Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid (2008) (16)
- Effects of leukemia inhibitory factor and oncostatin M on bone mineral formed in in vitro rat bone-marrow stromal cell culture: physicochemical aspects. (1998) (15)
- Leukemia inhibitory factor (LIF) and oncastsin M (OSM) high affinity binding require additional receptor subunits besides GP130 and GP190. (1996) (15)
- Three-dimensional in vitro culture models in oncology research (2022) (15)
- A Functional, New Short Isoform of Death Receptor 4 in Ewing's Sarcoma Cell Lines May be Involved in TRAIL Sensitivity/Resistance Mechanisms (2012) (15)
- Development of enzymo-immunoassays (EIA) for macrophage colony-stimulating factor (M-CSF) and leukaemia inhibitory factor (LIF) by using the same capture and signal generating polyclonal antibody. (1996) (15)
- Modulatory effects of proteoglycans on proteinase activities. (2012) (15)
- Hemophilia A and B mice, but not VWF−/−mice, display bone defects in congenital development and remodeling after injury (2019) (14)
- 12b80 - Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma. (2019) (14)
- Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells (2020) (14)
- Polymyxin B inhibits biphasic calcium phosphate degradation induced by lipopolysaccharide-activated human monocytes/macrophages. (1998) (13)
- Low‐Dose Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro (2019) (13)
- Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form. (1995) (13)
- Inhibition of Apatite Formation by Vitronectin (2000) (12)
- Microwave balloon angioplasty effectively seals arterial dissections in an atherosclerotic rabbit model. (1994) (12)
- Modulation of LIF expression in human melanoma cells by oncostatin M. (1995) (12)
- Leukemia Inhibitory Factor and Oncostatin M Influence the Mineral Phases Formed in a Murine Heterotopic Calcification Model: A Fourier Transform‐Infrared Microspectroscopic Study (1998) (12)
- Scanning electron microscopic description of cellular activity and mineral changes in feline odontoclastic resorptive lesions. (2001) (12)
- Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors. (2000) (12)
- Novel RANK Antagonists for the Treatment of Bone‐Resorptive Disease: Theoretical Predictions and Experimental Validation (2014) (12)
- Upmodulation of multinucleated cell formation in long-term human bone marrow cultures by leukaemia inhibitory factor (LIF). (1997) (11)
- Increased levels of leukaemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours. (1998) (11)
- Exosomal lncRNAs: the newest promising liquid biopsy (2019) (11)
- Influence of bone environment on ceramic osteointegration in spinal fusion: comparison of bone-poor and bone-rich sites (2001) (11)
- Circulating Tumor Cells: The Importance of Single Cell Analysis. (2018) (11)
- Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A (2018) (11)
- In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. (2018) (10)
- Bisphosphonates and bone diseases: past, present and future. (2010) (10)
- The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties (2021) (10)
- IL-6 inhibits RANKL-induced osteoclastogenesis by diverting cells into the macrophage lineage: Key role of serine727 phosphorylation of STAT3 (2008) (10)
- The intratumoral microbiome: Characterization methods and functional impact. (2021) (10)
- Frontiers in Medicinal Chemistry (2016) (10)
- Extraosseous Bone Formation Obtained by Association of Mesenchymal Stem Cells With a Periosteal Flap in the Rat (2007) (9)
- Growth hormone stimulates the degradation of calcium phosphate biomaterial by human monocytes macrophages in vitro. (1998) (9)
- Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. (2022) (9)
- Heterogeneity of B lineage acute lymphoblastic leukemias (B-ALL) with regard to their in vitro spontaneous proliferation, growth factor response and BCL-2 expression. (1996) (9)
- Constitutive Expression of TNF-Related Activation-Induced Cytokine (TRANCE)/Receptor Activating NF-κB Ligand (RANK)-L by Rat Plasmacytoid Dendritic Cells (2012) (9)
- Direct anti-cancer effect of oncostatin M on chondrosarcoma (2011) (9)
- Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells (2016) (9)
- Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? (2013) (9)
- Murine Models of Bone Sarcomas. (2019) (9)
- Centre de Ressources Biologiques-Tumorothèque: Bioresources and Associated Clinical Data Dedicated to Translational Research in Oncology at the Institut de Cancérologie de l’Ouest, France (2020) (8)
- Potential synergies between matrix proteins and soluble factors on resorption and proteinase activities of rabbit bone cells. (2001) (8)
- Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL (2013) (8)
- Pharmacodynamics of bisphosphonates in arthritis (2011) (8)
- [Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)]. (1996) (7)
- Useful Side Handle for Holding Needle During Ultrasound-Guided Regional Anesthesia (2008) (7)
- Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. (2017) (7)
- Pro-osteoclastic in vitro effect of Polyethylene-like nanoparticles: Involvement in the pathogenesis of implant aseptic loosening. (2016) (7)
- Cell-free circulating epimarks in cancer monitoring. (2020) (6)
- Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons. (2019) (6)
- The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma (2021) (6)
- Immune Environment and Osteosarcoma (2017) (6)
- Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups (2018) (6)
- In vitro three-dimensional cell cultures for bone sarcomas (2021) (6)
- Bone substitutes: new concepts (1999) (6)
- Jaw osteosarcoma models in mice: first description (2019) (6)
- Proteoglycans and osteolysis. (2012) (6)
- A“Proteoglycan Targeting Strategy” for the Scintigraphic Imaging and Monitoring of the Swarm Rat Chondrosarcoma Orthotopic Model (2011) (6)
- [In vitro assessment of combining osteogenic cells with macroporous calcium-phosphate ceramics]. (2001) (6)
- 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model (2013) (6)
- High and Low Affinity Receptors for Human Interleukin for DA Cells / Leukemia Inhibitory Factor on Human Cells (2001) (5)
- Ueber Pigment in der Arachnoides spinalis (2005) (5)
- Heterotopic implantation of mouse bone-marrow cells: an in vivo model allowing analysis of mineral phases during mineralization processes. (1998) (5)
- OSTEOSARCOMA (1988) (5)
- N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool (2020) (5)
- Bisphosphonates in common pediatric and adult bone sarcomas. (2020) (5)
- Interleukin-34: An enigmatic cytokine (2010) (5)
- FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence of biological activities beyond hemostasis. (2021) (5)
- Expression of leukemia inhibitory factor by cartilage‐forming tumors of bone: An immunohistochemical study (1999) (4)
- A One-Pot Synthesis of 1-Hydroxy-1,1-bis(phosphonic acid)s Starting from the Corresponding Carboxylic Acids. (2012) (4)
- Osteoprotegerin Induces CD34+ Differentiation in Endothelial Progenitor Cells (2018) (4)
- D Np 63 a Silences a miRNA Program to Aberrantly Initiate aWound-Healing Program That Promotes TGF b-Induced Metastasis (2016) (4)
- Culturing of cells from giant cell tumour of bone on natural and synthetic calcified substrata: the effect of leukaemia inhibitory factor and vitamin D3 on the resorbing activity of osteoclast-like cells (2004) (4)
- Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines (2021) (4)
- Growth hormone stimulates multinucleated cell formation in long-term bone marrow cultures. (1998) (4)
- Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma (2018) (3)
- P47. Therapeutic efficacy of soluble receptor activator of NF-kappaB delivered by non-viral gene transfer in a mouse model of osteolytic osteosarcoma (2008) (3)
- Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. (2008) (3)
- Impact of onco-pediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient (2011) (3)
- Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development (2020) (3)
- Primary Retention of Molars and RANKL Signaling Alteration during Craniofacial Growth (2020) (3)
- FVIII regulates the molecular profile of endothelial cells: functional impact on the blood barrier and macrophage behavior (2022) (2)
- FRI0020 BMP-2 and TGF-B Inhibit IL-34 Expression in Rheumatoid Arthritis Synovial Fibroblasts (2016) (2)
- Balloon surface changes after stent deployment: Influence of the crimping technique (2002) (2)
- [Arterial heterogeneity]. (2013) (2)
- Development of prohibitin ligands against osteoporosis. (2020) (2)
- ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells (2021) (2)
- Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma (2022) (2)
- Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro. (2013) (2)
- Effect of adding bone marrow to ceramic graft materials with different interconnectivities in lumbar arthrodesis (2013) (2)
- An exopolysaccharide produced by alteromonas infernus reduces lung metastasis and prolongs survival rate of osteosarcoma-bearing mice (2011) (2)
- Preclinical evidence of positive effect of l-MTP-PE alone or combined with zoledronic acid in osteosarcoma. (2014) (1)
- Current Status of Immunotherapy for Osteosarcoma and its Future Trends (2010) (1)
- P46. Proteoglycans are potential regulators of osteoprotegerin (OPG) antitumoral and anti-bone resorption activities in osteosarcoma (2008) (1)
- Novel targeted therapies of bone tumors and future directions (2012) (1)
- Biology of Bone Sarcomas and New Therapeutic Developments (2017) (1)
- Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the anti-tumor effect of midostaurin in vivo (2008) (1)
- Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma. (2012) (1)
- Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study. (1999) (1)
- [Physiopathology of tumor-induced osteolysis]. (1999) (1)
- Transcriptional inhibition of connexin 43 BY EWS-FLI1: Implication in tumor development of ewing's sarcoma (2012) (1)
- Factor viii/von willebrand factor complex inhibits rankl-induced osteoclastogenesis and controls cell survival (2009) (1)
- Therapeutic efficacy of soluble receptor activator of NF-kB (RANK) delivered by non viral gene transfer in a mouse model of osteolytic osteosarcoma (2008) (1)
- Characterisation of the Tumour Environment in Osteosarcoma: M1-Polarised Macrophages and Osteoprotegerin are Two Predictive Factors of the Metastastic Process (2015) (1)
- Proteoglycans are Potential Regulators of Osteoprotegerin (OPG) antitumoral and anti-bone resorption activities in osteosarcoma (2008) (1)
- Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma (2022) (1)
- Synergistic inhibition of osteosarcoma cell growth by combination of RAD001 (everolimus) and zoledronic acid (2009) (1)
- 79.Synergistic effect of Apomine and Lovastatin on osteosarcoma cell growth in vitro and in vivo (2010) (1)
- The Elderly and the COVID 19 Crisis: A Chronicle of Deaths Foretold, in Isolation and Total Indifference (2021) (1)
- Interleukin-34 and macrophage-colony stimulating factor interact to form a heteromeric and functional cytokine (2014) (1)
- mAbs targeting RANKL in bone metastasis treatment (2013) (1)
- Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study (2022) (1)
- RANK/RANKL Axis in Melanoma (2011) (1)
- Effects of a sulphated exopolysaccharide produced by alteromonas infernus on rat bone cells (2009) (1)
- Role of adam12 in osteosarcoma development and in TGFΒ/SMAD pathway activity (2012) (1)
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo (2013) (1)
- Role of osteoprotegerin (OPG) in angiogenesis (2012) (0)
- Late local reccurence of osteosarcoma after autologous fat grafts: Case report and pre-clinical data (2009) (0)
- Alpelisib. Phosphatidylinositol 3-kinase alpha (PI3K alpha) inhibitor Oncolytic (2015) (0)
- 191 Homotypic and heterotypic cell signaling transduction using a dielectrophoresis microfluidic device (2014) (0)
- Chondroitin sulfate chains are co-receptors for interleukin- 34 (2014) (0)
- repression of p73 controls Cisplatin chemoresistance in primary bone tumors (2016) (0)
- Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration (2014) (0)
- Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors (2013) (0)
- RANKL silencing by siRNA improves therapeutic response of primary osteosarcoma to conventional chemotherapy (2010) (0)
- New PI3K[alpha]-specific inhibitor, BYL719: therapeutic interest in osteosarcoma (2013) (0)
- Zoledronic acid slows down rat primary chondrosarcoma development, recurrente tumor progression after intralesional curretage and increases overall survival (2006) (0)
- P053Synergistic effect of apomine and lovastatin on osteosarcoma cell growth (2009) (0)
- Interleukin 34 promotes angiogenesis and increases blood cells adherence to endothelial cells (2014) (0)
- Abstract 4472: Targeting the oncogenic transcription factor EWS-Fli1 by BET bromodomain inhibition in Ewing sarcoma (2016) (0)
- Lessons to be learned from osteosarcoma (2011) (0)
- Chapter 6 Immune Environment and Osteosarcoma (2019) (0)
- In vitro cytotoxicity evaluation of three vasculary stents by direct contact (2002) (0)
- Abstract 4270: UMR957: a new osteogenic osteosarcoma cell-line derived from an osteoprotegerin null mutant mouse (2016) (0)
- Craniofacial consequences of high-dose zoledronic acid injections in onco-pediatric patients (2013) (0)
- Oral edelfosine lipid nanoparticles caused the regression of lung metastases in pre- clinical osteosarcoma animal models (2018) (0)
- Derivatives of hydroxy-bisphosphonic acid as a carrier targeting the bone tissue (2008) (0)
- Bone Modulating Bioactive Natural Compounds: Review (2007) (0)
- Peptides that target the receptor activator of nuclear factor kappa B (RANK) and its applications (2012) (0)
- Non-viral osteoprotegerin gene transfer inhibits the tumor progression and prolongs survival in a mouse experimental model of osteosarcoma (2006) (0)
- Abstract 1439: RANK expression by osteosarcoma cells increases lung metastasis in Nude mouse while has no effect in immune-competent mouse (2015) (0)
- Implication of autophagy in a preclinical mouse model of bone ageing and of osteoporosis (2016) (0)
- Osteoprotegerin inhibitits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL produced by tumor cells (2011) (0)
- Improvement of collagen synthesis in fibroblasts of Brtl model for osteogenesis imperfecta following lentiviral-shRNA-mediated down-expression of mutant Col1a1 allele (2013) (0)
- Preclinical evidence of craniofacial adverse effect of zoledronic acid in newborn mice: Potential consequences in pediatric osteosarcoma and Ewing’s sarcoma patients. (2014) (0)
- Human breast cancer cells educate macrophages toward the M2 activation status (2015) (0)
- Abstract B46: miRNA-193a-5p repression of p73 induces Cisplatine chemoresistance in bone-related sarcomas (2016) (0)
- miRNA-193a-5p of p73 controls cisplatin chemoresistance in primary bone tumors (2016) (0)
- Regulation of the activity of RANKL1 by proline-rich domain (2010) (0)
- Over-expression of Smad7 in osteosarcoma cells inhibits primary tumor growth, the associated bone osteolysis and the development of lung metastasis in murine xenograft model (2013) (0)
- AB0127 Resolution of Inflammation is Associated with an Inversion of the Synovial Tissue M1/M2 Ratio in the Antigene-Induced Arthritis Model (2015) (0)
- Characterization of dormancy in osteosarcoma cell lines cultured in 3D (2021) (0)
- Abstract 3289: Skeletal consequences of bone resorption inhibitors (zoledronic acid and RANKL blocking antibody) injections during growth: mouse strain disparities and synergic effect (2015) (0)
- DIRECT ANTI-TUMOUR EFFECT OF ZOLEDFROINIC ACID ON RAT OSTEOSARCOMA: THERAPEUTIC EFFECT IN COMBINATION WITH IFOSFAMIDE (2005) (0)
- PP492-T/NIOP08 (recipient of a 2011 ECTS/IBMS Travel Award)Trail sensitivity in Ewing's sarcoma patients is modulated by the expression of death receptor 4 and its short isoform despite predominant dr5 level (2011) (0)
- Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to theAntitumor Effect of Midostaurin In vivo Be ¤ ne ¤ (2008) (0)
- 179 Effects of human breast cancer cells secreted factors on macrophage differentiation (2014) (0)
- Calcifications in atherosclerotic plaques: Histological comparison between carotid and femoral location (2009) (0)
- 3 MAJOR ROLE OF PERICYTES IN THE CALCIFICATION OF ATHEROMATOUS ARTERIES (2011) (0)
- Oncostatin M leads to opposite effects on the proliferation of different primary bone tumors (2010) (0)
- Mammalian models of bone sarcomas (2022) (0)
- Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients (2022) (0)
- New therapeutic approaches of osteosarcoma by rna interference (2009) (0)
- Alveolar bone changes and the role of osteoclasts in zoledronic acid - treated mice (2013) (0)
- Osteoprotegerin and bone-like vascular calcification are predictive markers of vulnerable carotid plaques (2014) (0)
- Process for the synthesis of derivatives of hydroxy-bisphosphonic acid (2008) (0)
- Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast S. boulardii CNCM I-745 reduces bone loss in osteoporosis (2022) (0)
- Bone microenvironment associated to wear debris in temporomandibular joint implants: pre-clinical model in mice (2011) (0)
- Scandium exopolysaccharide complexes: evaluation of antiproliferative properties of on several cancer cell lines (2022) (0)
- Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment (2022) (0)
- INTERNALISATION OF PROPIONIBACTERIUM ACNES BY OSTEOBLASTS DEPENDS ON P. ACNES GENETIC BACKGROUND (2016) (0)
- Abstract 1750: Preclinical efficacy of Hsp90 inhibition by using PF-04942847 in osteosarcoma (2015) (0)
- Osteoblast Differentiation of Mesenchymal Stem Cells in Different 3D Culture Models: Issues in the Study of Bone Tumours (2015) (0)
- TNF-Related Apoptosis Inducing Ligand (TRAIL) inhibits primary bone tumor growth and augments survival in a human model ewing sarcoma (2008) (0)
- High and low affinity receptors for the human lymphokine hilda lif binding properties and molecular structure (1991) (0)
- Regulation of cancer-induced osteoclastogenesis by exogenous and tumour-derived Sema3A (2015) (0)
- Evaluation in vitro de la cytotoxicité de trois endoprothèses vasculaires par contact direct (2002) (0)
- Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A (2018) (0)
- Jaw osteosarcoma models in mice: first description (2019) (0)
- MNNG-HOS osteosarcoma growth is enhanced by human fat and adipose-derived mesenchymal stem cells: Implication in reconstructive surgery following tumor treatment (2011) (0)
- Pharmacological options in the treatment of osteogenesis imperfecta: a comprehensive review of clinical and potential alternatives (2023) (0)
- Three-dimensional in vitro culture models in oncology research (2022) (0)
- 1 Cancer stem cells in Osteosarcoma (2019) (0)
- Abstract B53: Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors (2013) (0)
- A Simple 3D Cell Culture Method for Studying the Interactions between Human Mesenchymal Stromal/Stem Cells and Patients Derived Glioblastoma (2023) (0)
- Zoledronic acid induces osteosarcoma cell death by aif translocation and cell cycle arrest in S and G2/M phases (2006) (0)
- Preclinical efficacy of PF-04942847, a novel HSP90 inhibitor, in osteosarcoma (2014) (0)
- [Contribution of in vitro models (cell cultures and growth factors)]. (2000) (0)
- EFFECT OF ZOLEDRONIC ACID ON CHONDROSARCOMA: IN VITRO AND IN VIVO STUDY USING A RAT MODEL (2008) (0)
- [In vitro effects of growth hormone on osteoclastic activity: clinical applications]. (2000) (0)
- Bioimaging: Are Fluorescent Organic Nanoparticles Relevant Tools for Tracking Cancer Cells or Macrophages? (Adv. Healthcare Mater. 17/2015). (2015) (0)
- Specific suppression of the mutant COL1A1 allele by siRNA/shRNA in fibroblasts of the osteogenesis imperfecta murine model BrtlIV (2011) (0)
- Therapeutic interest of Imatinib Mesylate in osteosarcoma (2013) (0)
- The reborne project: regenerating bone in patients using autologous mesenchymal stem cells (2015) (0)
- Osteosarcoma. (2022) (0)
- Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer (2022) (0)
- THU0524 IL-1-β and Tnf-α Promote Monocyte Survival and Proliferation through the Induction of GM-CSF Expression by Rheumatoid Arthritis Synovial Fibroblasts (2014) (0)
- Abstract LB-142: Selective inhibition of BET bromodomains epigenetic signaling interferes with the bone-associated tumor vicious cycle (2014) (0)
- Cancer esearch apeutics , Targets , and Chemical Biology dronic Acid as a New Adjuvant Therapeutic Strategy R Ewing ' s Sarcoma Patients (2010) (0)
- Zoledronic acid as new adjuvant therapeutic agent for Ewing's sarcoma (2009) (0)
- Inhibition of TGF-β signaling pathway blocks the development of osteosarcoma lung metastases (2014) (0)
- Proteases and Therapeutic Approaches of Bone Tumors (2010) (0)
- Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate (2014) (0)
- Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1 (2023) (0)
- Mechanistic study of the proangiogenic effect of osteoprotegerin (2013) (0)
- Oncostatin M is a growth factor for ewing sarcoma: Potent role of the leukemia inhibitory factor receptor (2011) (0)
- ' s report Title : Regulation of Interferon Pathway in 2-Methoxyestradiol-treated Osteosarcoma Cells Version : 1 Date : 21 September 2011 (0)
- Glycosaminoglycans inhibit rankl-induced osteoclastogenesis (2009) (0)
- P45. TNF-related apoptosis-inducing ligand (TRAIL) inhibits primary bone tumor growth and augments survival in a human model Ewing sarcoma (2008) (0)
- Abstract 1911: ΔNp63α promotes TGFβ-induced metastasis by silencing a microRNA network restraining wound healing (2016) (0)
- Preclinical evidence of using TRAIL in Ewing's sarcoma therapy (2009) (0)
- Interleukin-34 and Pathogenesis of Osteosarcoma: Involvement in the Tumour Progression and the Metastatic Process by Modulating Macrophage Infiltration and Neovascularisation (2015) (0)
- 7.O.08 ZOLEDRONIC ACID AS NEW ADJUVANT THERAPEUTIC AGENT FOR EWING’S SARCOMA (2010) (0)
- Liquid biopsy in bone sarcomas and identification of new biomarkers (2022) (0)
This paper list is powered by the following services:
Other Resources About Dominique Heymann
What Schools Are Affiliated With Dominique Heymann?
Dominique Heymann is affiliated with the following schools:
